Published in Neurology on January 25, 2005
High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology (2009) 3.04
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology (2010) 2.84
Changes in network activity with the progression of Parkinson's disease. Brain (2007) 2.46
Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab (2006) 2.42
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord (2008) 1.49
Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol (2007) 1.42
Neuroimaging and therapeutics in movement disorders. NeuroRx (2005) 1.17
Is PET always an advantage versus planar and SPECT imaging? Eur J Nucl Med Mol Imaging (2008) 1.15
VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem (2007) 1.15
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol (2007) 1.07
Neuroimaging in Parkinson's disease. Neurotherapeutics (2011) 0.95
Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol (2013) 0.95
Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron (2014) 0.93
Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. Neurosci Lett (2007) 0.93
Translating principles of neural plasticity into research on speech motor control recovery and rehabilitation. J Speech Lang Hear Res (2008) 0.92
Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics (2014) 0.92
18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol (2007) 0.92
Low nigrostriatal reserve for motor parkinsonism in nonhuman primates. Exp Neurol (2012) 0.89
Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem (2010) 0.89
Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease. Eur J Nucl Med Mol Imaging (2007) 0.89
Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics (2008) 0.88
Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. PLoS One (2010) 0.87
Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. J Biomed Biotechnol (2012) 0.87
The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging (2008) 0.87
Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging (2006) 0.86
Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques. Ann Neurol (2013) 0.86
Neuroimaging biomarkers for Parkinson disease: facts and fantasy. Ann Neurol (2014) 0.83
Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. BMC Neurol (2011) 0.82
EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 0.82
Multiple protonation states of vesicular acetylcholine transporter detected by binding of [3H]vesamicol. Biochemistry (2009) 0.82
Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image. PLoS One (2015) 0.82
CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. Brain Res (2011) 0.81
Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm (Vienna) (2006) 0.81
α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease. Int J Mol Sci (2010) 0.81
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci (2016) 0.80
Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.79
Molecular functional imaging in personalized clinical oncology: The road less traveled. Indian J Med Paediatr Oncol (2016) 0.79
Fully Automated Quantification of the Striatal Uptake Ratio of [(99m)Tc]-TRODAT with SPECT Imaging: Evaluation of the Diagnostic Performance in Parkinson's Disease and the Temporal Regression of Striatal Tracer Uptake. Biomed Res Int (2015) 0.78
PET molecular imaging in stem cell therapy for neurological diseases. Eur J Nucl Med Mol Imaging (2011) 0.78
Human gene therapy and imaging in neurological diseases. Eur J Nucl Med Mol Imaging (2005) 0.77
Heterogeneity of Monosymptomatic Resting Tremor in a Prospective Study: Clinical Features, Electrophysiological Test, and Dopamine Transporter Positron Emission Tomography. Chin Med J (Engl) (2015) 0.77
Proceedings: cell therapies for Parkinson's disease from discovery to clinic. Stem Cells Transl Med (2014) 0.75
Expert testimony at the Food and Drug Administration: who wants the truth? Narrat Inq Bioeth (2011) 0.75
T2-relaxometry predicts outcome of DBS in idiopathic Parkinson's disease. Neuroimage Clin (2016) 0.75
Imaging genetics approach to Parkinson's disease and its correlation with clinical score. Sci Rep (2017) 0.75
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 0.75
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 0.75
Recent progress of imaging agents for Parkinson's disease. Curr Neuropharmacol (2014) 0.75
Recent Updates on Acquired Hepatocerebral Degeneration. Tremor Other Hyperkinet Mov (N Y) (2017) 0.75
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
The Physiological Effects of Extracts of the Suprarenal Capsules. J Physiol (1895) 14.49
The functional anatomy of basal ganglia disorders. Trends Neurosci (1989) 12.28
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
Prox1 function is required for the development of the murine lymphatic system. Cell (1999) 7.57
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science (1989) 7.03
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology (2006) 6.86
How common are the "common" neurologic disorders? Neurology (2007) 6.77
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
On the Physiological Action of Extracts of Pituitary Body and certain other Glandular Organs: Preliminary Communication. J Physiol (1895) 6.35
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med (2000) 6.21
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 6.03
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
Parkinson disease in twins: an etiologic study. JAMA (1999) 5.45
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet (1997) 5.39
Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet (1995) 5.11
Quantitative magnetic resonance imaging of human brain development: ages 4-18. Cereb Cortex (1996) 5.08
Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol (1999) 4.97
The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature (1997) 4.69
Double-blind study of botulinum toxin in spasmodic torticollis. Lancet (1986) 4.54
Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology (2007) 4.28
Do formal advance directives affect resuscitation decisions and the use of resources for seriously ill patients? SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. J Clin Ethics (1994) 4.23
Two-dimensional versus three-dimensional cell counting: a practical perspective. Trends Neurosci (2001) 4.09
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology (2006) 4.06
Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet (2001) 3.84
Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain (2007) 3.82
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
In-vivo measurement of activated microglia in dementia. Lancet (2001) 3.51
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
Revascularization results in the Interventional Management of Stroke II trial. AJNR Am J Neuroradiol (2008) 3.32
Evidence for striatal dopamine release during a video game. Nature (1998) 3.28
Quantitative MRI of the temporal lobe, amygdala, and hippocampus in normal human development: ages 4-18 years. J Comp Neurol (1996) 3.25
Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med (1996) 3.23
Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry (1980) 3.19
Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science (2001) 3.18
Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet (1997) 3.11
Depletion and disruption of dietary fibre. Effects on satiety, plasma-glucose, and serum-insulin. Lancet (1977) 3.08
Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci (1999) 3.06
Prox1 function is crucial for mouse lens-fibre elongation. Nat Genet (1999) 3.01
In a minority of gay men, sexual risk practice indicates strategic positioning for perceived risk reduction rather than unbridled sex. AIDS Care (2002) 3.01
Superficial siderosis. Neurology (2006) 2.98
The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. Neuroepidemiology (1997) 2.96
Synthesis and characterization of phosphorescent cyclometalated iridium complexes. Inorg Chem (2001) 2.94
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology (2007) 2.86
Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol (1996) 2.86
The functional anatomy of motor recovery after stroke in humans: a study with positron emission tomography. Ann Neurol (1991) 2.84
Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology (1999) 2.81
Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A (1988) 2.78
Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord (1994) 2.77
Practice parameters for the treatment of sigmoid diverticulitis--supporting documentation. The Standards Task Force. The American Society of Colon and Rectal Surgeons. Dis Colon Rectum (2000) 2.77
Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry (1996) 2.76
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Aversive properties of the negative stimulus in a successive discrimination. J Exp Anal Behav (1969) 2.75
Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology (2003) 2.73
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology (2007) 2.72
Motor sequence learning: a study with positron emission tomography. J Neurosci (1994) 2.71
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology (2004) 2.70
Cognitive impairment after ECT in patients with Parkinson's disease and psychiatric illness. Am J Psychiatry (1992) 2.68
Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab (1996) 2.66
Efficacy and safety of pramipexole in restless legs syndrome. Neurology (2006) 2.63
Highly phosphorescent bis-cyclometalated iridium complexes: synthesis, photophysical characterization, and use in organic light emitting diodes. J Am Chem Soc (2001) 2.61
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology (1985) 2.58
The Neurobehavioral Cognitive Status Examination: a brief but quantitative approach to cognitive assessment. Ann Intern Med (1987) 2.58
Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology (2012) 2.50
REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology (2010) 2.50
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology (2000) 2.49
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41
Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology (2001) 2.41
Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience (1994) 2.40
The DYT1 phenotype and guidelines for diagnostic testing. Neurology (2000) 2.39
D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry (1998) 2.36
Bilateral human fetal striatal transplantation in Huntington's disease. Neurology (2002) 2.34
Situs revisited: imaging of the heterotaxy syndrome. Radiographics (1999) 2.33
Aetiology of Parkinson's disease. Lancet (1984) 2.32
Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology (2000) 2.31
Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol (2001) 2.31
Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis (2004) 2.29
Anatomy of motor learning. I. Frontal cortex and attention to action. J Neurophysiol (1997) 2.29
Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry (1999) 2.27
Volunteering for early phase gene transfer research in Parkinson disease. Neurology (2006) 2.27
Carotid endarterectomy--an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2005) 2.26
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit. Ann Neurol (1999) 2.26
Granulocytic sarcoma in childhood leukemia: imaging features. Radiology (1994) 2.26
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006) 2.25
Large DNA restriction fragment polymorphism in the Mycobacterium avium-M. intracellulare complex: a potential epidemiologic tool. J Clin Microbiol (1993) 2.25
Dissociations of cerebral cortex, subcortical and cerebral white matter volumes in autistic boys. Brain (2003) 2.24